title: BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma.
abstract: Fifty-two samples of pediatric low-grade glioma (48 primary, 4 recurrent) were analyzed for BRAF copy number variation (digital PCR analysis, CopyCaller) and point mutations of BRAF V600E, and exon 5 Q209 in GNAQ, and GNA11, using the MALDI-TOF mass spectrometer with validation by direct sequencing. An increased BRAF copy number was found in 18/47 primary samples tested; 15 of them (83.3%) were pilocytic astrocytomas. A BRAF mutation was found in 3/48 primary tumors, all with a normal BRAF copy number and no GNAQ mutation. One sample had a GNAQ209 mutation (Q209P626) with a normal BRAF gene; none of the tumors had a GNA11Q209 mutation. Recurrent or progressive tumors, analyzed in four patients, had the same molecular genotype as their primary. Increased BRAF copy number and activating BRAF mutations may be involved in the development of low-grade glioma via overactivation of the Ras/Raf pathway. This is the first report of a mutation in GNAQ209 in pediatric low-grade glioma. Understanding the molecular mechanisms underlying glioma initiation and growth may assist in the development of targeted therapies.
authors: Department of Neurosurgery, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
authors: Yosef
authors: Y
authors: Laviv
authors: Helen
authors: H
authors: Toledano
authors: Shalom
authors: S
authors: Michowiz
authors: Olga
authors: O
authors: Dratviman-Storobinsky
authors: Yuval
authors: Y
authors: Turm
authors: Suzana
authors: S
authors: Fichman-Horn
authors: Ella
authors: E
authors: Kagnovski
authors: Nitza
authors: N
authors: Goldenberg-Cohen
keywords: BRAF mutation; Copy number variation; GNAQ/GNA11; Low-grade glioma; Pediatric
references: J Clin Invest. 2008 May;118(5):1739-49
references: 18398503
references: J Pathol. 2009 Jun;218(2):172-81
references: 19373855
references: J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
references: 15977639
references: Neoplasia. 2008 May;10(5):501-10
references: 18472967
references: Br J Cancer. 2007 Jan 15;96(1):16-20
references: 17179987
references: Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3027-30
references: 16123397
references: Nature. 2009 Jan 29;457(7229):599-602
references: 19078957
references: Pediatr Blood Cancer. 2008 Aug;51(2):245-50
references: 18386785
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2876-8
references: 12824225
references: Oncogene. 2008 Aug 7;27(34):4745-51
references: 18408760
references: J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87
references: 18716556
references: Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4
references: 18719078
references: Cancer Res. 2007 Mar 15;67(6):2632-42
references: 17363583
references: Cancer Res. 1997 Oct 1;57(19):4187-90
references: 9331072
references: J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8
references: 17878251
references: Int J Cancer. 2011 Nov 1;129(9):2297-303
references: 21190184
references: Brain Pathol. 2009 Apr;19(2):279-92
references: 18616639
references: Cancer Res. 2008 Nov 1;68(21):8673-7
references: 18974108
references: BMC Cancer. 2004 Sep 14;4:65
references: 15367334
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Cell Signal. 2006 Feb;18(2):135-50
references: 16182515
references: Curr Opin Oncol. 2008 Mar;20(2):183-9
references: 18300768
references: Klin Padiatr. 2004 Nov-Dec;216(6):331-42
references: 15565548
references: Brain Pathol. 2009 Jul;19(3):449-58
references: 19016743
references: Endocr Pathol. 2005 Summer;16(2):99-105
references: 16199894
references: J Cell Physiol. 2010 Mar;222(3):509-14
references: 19937730
references: PLoS One. 2009 Aug 31;4(8):e6833
references: 19718445